ImpediMed Inc. news

New Bone Data Comparing ImpediMed’s SOZO to DXA in Cancer Patients to be Presented at 39th Annual Miami Breast Cancer Conference

ImpediMed Limited (ASX.IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximize patient health is pleased to announce an abstract comparing concurrent measures using ImpediMed’s SOZO® Digital Health Platform and dual x-ray absorptiometry (DXA) for assessing in bone mineral content in cancer patients was accepted for poster presentation at the 39th Ann

Feb. 15, yyyy

New Data Show Statistically Significant Reduction in Chronic Cancer-Related Lymphedema with Early Detection Using ImpediMed’s L-Dex® Technology and Intervention

Lymphatic Research and Biology Publishes Data on PREVENT, the Largest Randomized Trial to Assess Lymphedema Prevention
L-Dex Technology Provides a New Standard Approach for Prevention of Cancer-Related Lymphedema

ImpediMed Limited (ASX: IPD), a global medical technology company using bioimpedance spectroscopy (BIS) to generate powerful data to maximize patient health, today announced publication of results from the PREVENT trial

Feb. 1, yyyy